Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33106290.
- Also identified by DOI 10.1158/1078-0432.CCR-20-3506 and PMC identifier 7785667.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.<i>See related article by Tannir et al., p. 78</i>.
Medical subject headings
- Carcinoma, Renal Cell
- Kidney Neoplasms